Globe Life Inc. (GL) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is moderately constructive — consensus is a manageable bar, guidance was raised at Q1, and the stock has already re-rated +22% since last earnings, meaning the market has priced in a solid print; the wildcard is whether American Income agent count recovery is on track for H2 as management guided.

Globe Life heads into Q2 2026 earnings with a raised guidance bar ($15.40–$15.90 FY EPS, up from $14.95–$15.65) and a stock that has already re-rated ~22% since the April 22 print, compressing the upside optionality. Consensus Q2 EPS sits at $3.69, implying ~13% YoY growth, which is achievable given management’s explicit Q2 life margin guidance of ~41% and health margin guidance of “north of 25%.” The key debate heading in is whether American Income’s agent count — which declined YoY in Q1 due to new agent retention issues — is showing early signs of recovery following the Q2 compensation structure adjustments; management guided to H2 recovery, and any color on Q2 agent trends will be closely watched. The Bermuda reinsurance entity filing for reciprocal jurisdiction status (guided for Q2) is a potential positive catalyst if management provides a more substantive update on the capital generation timeline. The wildcard is health underwriting margin: United American Medicare Supplement rate increases are earning in through 2026, and any upside surprise there (management guided “north of 25%” for Q2–Q4) could drive estimate revisions higher.

• Bar: Consensus Q2 EPS of $3.69 is a manageable bar — management explicitly guided life margin ~41% and health margin “north of 25%” for Q2, so the Street is essentially tracking guidance.
• Guidance/Tone: Management raised FY 2026 EPS guidance at Q1 to $15.40–$15.90 (from $14.95–$15.65) and narrowed excess cash flow to $650–$700M; tone was confident on mortality trends and Medicare Supplement rate recovery.
• Estimate Trajectory: Estimates have been stable-to-slightly-up since Q1 earnings; Q2 consensus of $3.69 is down modestly from the $3.72 post-Q1 baseline (slight drift), while FY consensus of $15.67 is roughly in line with guidance midpoint.
• Stock Setup: GL has rallied +22% since Q1 earnings vs. +10% for KIE and +5% for SPY — the stock has clearly re-rated and is no longer cheap relative to its own history; a beat-and-raise is likely needed to sustain momentum.
• Wildcard: American Income agent count trajectory in Q2 — management implemented compensation adjustments at the start of Q2 to fix new agent retention; any early data point on whether this is working will be the most market-moving disclosure.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is tracking management’s explicit Q2 guidance on margins; the bigger swing factor is health premium growth (Medicare Supplement rate increases) and whether agent count recovery is visible.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha consensus and actuals data. Q2 2026 consensus as of July 21, 2026.

Table 2 — Beat/Miss History (Last 8 Quarters)

Net Operating EPS

Pattern: GL has beaten on EPS in 5 of the last 8 quarters; the two most recent quarters were slight misses, though both were within ~1.5% of consensus. Q3 beats are structurally elevated by assumption updates.

Life Underwriting Margin (%)

Pattern: Life underwriting margin has beaten or met consensus in every quarter of the last 8; favorable mortality trends have been a consistent tailwind, and management has been conservative in setting guidance.

3. Guidance & Commentary Evolution

Key Takeaway: FY 2026 EPS guidance was raised at Q1 earnings; no post-earnings revisions since then. Tone remains confident on mortality and Medicare Supplement recovery.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been broadly stable since Q1 earnings, tracking management’s raised guidance; the slight downward drift in Q2 EPS consensus (from $3.72 to $3.69) is immaterial and within normal revision noise.

Estimates have been remarkably stable since Q1 earnings, with virtually no revision activity. The slight downward drift in Q2 EPS (-0.8%) and health margin (-10 bps) is within normal noise. The FY EPS consensus of $15.67 sits essentially at the midpoint of management’s $15.40–$15.90 guidance range, suggesting the Street is not pricing in meaningful upside or downside from guidance.

5. Stock Performance

Key Takeaway: GL has significantly outperformed both the insurance sector (KIE) and the broader market (SPY) since Q1 earnings, driven by multiple expansion on raised guidance and improving fundamentals — the stock is no longer cheap and needs execution to sustain.

GL vs. KIE (SPDR S&P Insurance ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (April 22, 2026). Source: Stock Price Data.

GL has rallied +21.9% since Q1 2026 earnings (April 22, 2026) vs. +9.9% for KIE (SPDR S&P Insurance ETF) and +5.2% for SPY. The outperformance is driven by: (1) raised FY 2026 EPS guidance at Q1 earnings, (2) improving Medicare Supplement margin trajectory as rate increases earn in, (3) accelerated share repurchases ($205M in Q1 alone), and (4) the Bermuda reinsurance entity progressing toward reciprocal jurisdiction status. The credit facility refinancing on June 26, 2026 (extending maturity to 2031 and expanding the term loan to $450M) was a modest positive, signaling balance sheet confidence. The stock’s re-rating from ~$151 to ~$184 has compressed the valuation discount to peers, and the setup into Q2 earnings is more balanced than it was heading into Q1.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the credit facility refinancing, which extends GL’s debt maturity profile and signals financial flexibility; the Bermuda entity update expected on the Q2 call is the key catalyst to watch.

• June 26, 2026 — Credit Facility Refinancing (8-K filed June 29): Globe Life refinanced its credit facilities, extending the revolving credit facility maturity to June 2031 (from March 2029) and expanding the term loan to $450M (from $250M), with Wells Fargo replacing Bank of America as administrative agent. Implication: Extends debt maturity runway, reduces near-term refinancing risk, and signals balance sheet confidence heading into the Bermuda capital structure buildout.
• April 22, 2026 — Q1 2026 Earnings: FY 2026 EPS guidance raised to $15.40–$15.90 (from $14.95–$15.65); excess cash flow range narrowed to $650M–$700M; share repurchase guidance increased to $560M–$610M; 22% annual dividend increase announced. American Income agent count declined YoY due to new agent retention issues; compensation adjustments implemented at start of Q2 to address.
• Q2 2026 (expected) — Bermuda Reinsurance Entity Update: Management guided to file for reciprocal jurisdiction status in Q2 2026 and promised a “more significant update” on the Q2 call. The Bermuda entity (formed and licensed December 2025) is expected to generate ~$200M of additional annual excess cash flow starting 2027. Any concrete timeline or capital generation detail would be a meaningful positive catalyst.
• April 30, 2026 — Annual Shareholder Meeting: Shareholders approved executive compensation and incentive plan; two new independent directors (Kan and Phillips) added to the board in February 2026, expanding it to 14 members.

7. Peer Commentaries — Read-Through for Q2 2026

Key Takeaway: Peer Q1 2026 earnings calls (reported April–May 2026) contained forward-looking commentary directly relevant to GL’s Q2 2026 setup — the most important read-throughs are: (1) continued favorable working-age mortality across the industry, (2) Medicare Supplement tailwinds from MA-to-MedSupp migration, and (3) elevated lapse rates from economic stress, consistent with GL’s own guidance.

Note: All commentary below is from Q1 2026 earnings calls (reported April 29 – May 7, 2026), which contain forward-looking guidance about Q2 2026 and the remainder of 2026. This is current-quarter read-through commentary, not backward-looking results.

Mortality Trends — Broadly Favorable, Consistent with GL’s Guidance

• Lincoln Financial (LNC, Q1 2026 call, May 7): “Mortality this quarter was favorable to our expectations, driven primarily by continued favorable experience within our term business. The result is consistent with the improvement we have seen in recent quarters and with broader U.S. mortality trends, which have continued to move in a favorable direction.” For Q2 2026, LNC guided to “a modest improvement in mortality as favorable seasonal trends from the first to second quarter are partly offset by the favorable experience in the first quarter.” Read-through: Favorable mortality trends are industry-wide and expected to continue into Q2, supporting GL’s ~41% life underwriting margin guidance.
• MetLife (MET, Q1 2026 call, May 7): “Life mortality in the quarter was exceptional, as working population mortality continues to trend favorably and was further helped by a light flu season this year.” Group Life mortality ratio was 80.1%, better than MET’s 2026 target range of 83%–88%. Management noted potential drivers include “a pull-forward effect from a COVID perspective, some include the impact of GLP-1 drugs.” Read-through: Favorable working-age mortality is a structural tailwind for GL’s life underwriting margins, not just a one-quarter phenomenon.
• Unum Group (UNM, Q1 2026 call, April 29): Group Life and AD&D achieved “record levels of earnings” with a benefit ratio of 61.8% vs. 69.3% in Q1 2025, “driven by lower incidents.” Management believes “this moderate level of outperformance could continue to persist.” Read-through: Favorable mortality is broad-based across group life writers, reinforcing GL’s ability to sustain ~41% life underwriting margins in Q2.

Medicare Supplement — Structural Tailwind Confirmed

• CNO Financial (CNO, Q1 2026 call, May 1): Medicare Supplement NAP was up 53% in Q1 2026, with total Medicare policies sold up 24%. CNO noted that “approximately 3 million MA members had their plans terminated for the 2026 plan year, requiring them to find new coverage” and “about 1 in 5 people with Medicare switched plans or carriers, the highest rate ever recorded for an annual enrollment period.” CNO filed for Medicare Supplement rate increases of 10.2% (effective Jan 1, 2026) and expects approvals of ~14.5% for July 1, 2026 effective dates. Read-through: The MA-to-MedSupp migration tailwind that drove GL’s United American health sales surge in Q1 is a structural, multi-year trend. CNO’s rate increase filings (10–16% range) are consistent with GL’s own rate increase strategy and validate the margin recovery thesis.
• CNO Financial (CNO, Q1 2026 call, May 1): CEO Gary Bhojwani stated he remains “extremely bullish” on demand, citing “11,000 people turning 65 every day, absence of alternatives, longer lifespans, and the government’s inability to solve this problem.” Read-through: Secular demand for Medicare Supplement products remains robust, supporting GL’s United American health sales growth guidance of “high teens” for FY 2026.

Agent Recruiting — Mixed Industry Picture, GL’s Challenge Not Unique

• Aflac (AFL, Q1 2026 call, April 30): “Recruiting is tough in the market. It’s not easy, but however, I can tell you that we’re going to be on track to recruit about consistent with what we’ve been for the last 2 or 3 years. We’ve been at that 10,000 to 11,000 range now.” The conversion rate of new agents in Q1 was 16%, with agent productivity up ~8%. Read-through: Agent recruiting challenges are industry-wide, not GL-specific. However, AFL’s focus on conversion and retention mirrors GL’s Q2 compensation adjustment strategy at American Income — the question is whether GL’s specific fix is working.
• CNO Financial (CNO, Q1 2026 call, May 1): Producing agent count was up 3% in Q1 2026, marking the 13th consecutive quarter of growth, with agent recruiting up 8% in the Worksite division. Read-through: CNO’s continued agent count growth (in contrast to GL’s American Income decline) suggests the challenge at GL is division-specific rather than macro-driven — consistent with management’s own characterization.

Consumer Financial Stress / Lapse Rates — Elevated but Manageable

• Aflac (AFL, Q1 2026 call, April 30): U.S. premium persistency remained solid at 79.3%. “We haven’t seen an impact [from inflation or higher gas prices]… we’re not seeing any material impact that’s worthy of calling out.” Read-through: Voluntary insurance persistency has held up despite macro stress, which is modestly positive for GL’s lapse rate outlook (management guided lapse rates to remain “elevated vs. pre-pandemic” but consistent with 2025 experience).
• MetLife (MET, Q1 2026 call, May 7): “Employers continue to see the value of benefits beyond medical coverage as a cost-effective way to support their employees’ health and financial security journeys in a tight economy.” Read-through: Demand for supplemental insurance products remains resilient even in a “tight economy,” supporting GL’s lower-middle income market positioning.

Health Claims Seasonality — Q1 Elevated, Q2 Recovery Expected Industry-Wide

• Lincoln Financial (LNC, Q1 2026 call, May 7): Elevated disability incidence in paid family leave from new states, expected to moderate through the year. Group Protection risk results “have historically improved from the first to the second quarter, and we expect that seasonal pattern to repeat this year.” Read-through: Seasonal improvement in health/disability claims from Q1 to Q2 is a broad industry pattern — consistent with GL’s own health margin guidance of “north of 25%” for Q2 vs. 22.7% in Q1.
• MetLife (MET, Q1 2026 call, May 7): Nonmedical health benefit ratio was 75.8% in Q1, above the 70%–75% annual target, driven by “seasonally higher dental utilization.” MET expects “utilization to moderate in the second half of the year.” Read-through: Q1 health seasonality is a broad industry phenomenon; GL’s Q1 health margin of 22.7% (below the 23%–27% FY guidance) is consistent with this pattern, and Q2 recovery to “north of 25%” is well-supported by peer commentary.

8. Insider Transaction Activity

Key Takeaway: All insider transactions since Q1 earnings are option exercises followed by same-day sales — a routine compensation-driven pattern with no discretionary open-market buying or selling. No unusual signals.

All transactions are option exercises immediately followed by same-day sales — a standard compensation realization pattern with no informational content about management’s view of the stock. There are no discretionary open-market purchases or sales. The absence of open-market buying is notable given the stock’s ~22% rally since Q1 earnings, but not alarming given the routine nature of all activity.